Investor Relations
Stock Information
News & Events
Presentations and Publications
Financials
Corporate Governance
Shareholder Services

Investor Relations

Corporate Profile

Neothetics is a clinical-stage specialty pharmaceutical company focused on development and commercialization of therapeutics for the aesthetic market. Our current focus is on localized fat reduction and body contouring. Neothetics’ lead product candidate, LIPO-202, is a injectable treatment for undesirable, localized areas of fat with no downtime and causes no damage below the skin’s surface. Our clinical studies with LIPO-202 do not use local or systemic pain management before or after the procedure.

Stock Information
NEOT (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.35
Change (%) Stock is Down 0.01 (2.78%)
Volume194,337
Data as of 08/18/17 4:00 p.m. ET
Stock chart for: NEOT.O.  Currently trading at $0.35 with a 52 week high of $2.63 and a 52 week low of $0.30.
Recent Presentations
There are currently no items available.


Recent Publications
DateTitle
03/20/15
Download Documentation AESTHETIC TREATMENT OF CENTRAL ABDOMINAL BULGING (CAB) WITH LIPO-202 (SALMETEROL XINAFOATE FOR INJECTION)
Recent NewsMore >>
DateTitle  
08/10/17Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the second quarter 2017. In July 2017, Neothetics announced that its Board of Directors unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash reso... 
Download PDFPrinter Friendly Version
07/10/17Neothetics Announces Review of Strategic Alternatives
SAN DIEGO, July 10, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) announced today that its Board of Directors has unanimously approved plans to initiate a process to explore and review a range of strategic alternatives focusing on seeking an acquisition, business combination or partnership that will allow for it to maximize shareholder value from its remaining assets and cash resources. Neothetics has engaged Oppenheimer and Co., Inc.  to act as its exclusive financial advisor to the... 
Download PDFPrinter Friendly Version
06/26/17Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
LIPO-202 did not show efficacy in the reduction of submental fat SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo... 
Download PDFPrinter Friendly Version
05/11/17Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017. “We are extremely pleased with the progress made during the quarter,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors.  “If approved, LIPO-202 could be the first non-ablative option for... 
Download PDFPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Neothetics, Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data Provided by Thomson Reuters
Minimum 20 minutes delayed